

()

“ ”

», ,

: , , , .

).

1-

10 / . ,

100

.HNP

[7]. HBD2 HBD3

, HBD1,

HBD3

HBD.

HBD4,
Pseudomonas

aeruginosa [8].

[1].

in vitro

HBD2 HBD4

Pseudomonas aeruginosa

50

(50% HBD).

[2].

[9].

1

[10].

in vitro

[11,12,13].

(

[3,5,6]

« » (.1). 1

Candida

		(/)
HNP1 (-)	<i>Listeria monocytogenes</i>	39,7
	<i>Staphylococcus epidermis</i>	5,2
	<i>Staphylococcus aureus</i>	2,2
	MRSA	21,2
	<i>Bacillus subtilis</i>	6,4
	VREF	11,9
	<i>Escherichia coli</i>	1,8
	<i>Salmonella typhimurium</i>	8,4
	<i>Pseudomonas aeruginosa</i>	>250
	<i>Burkholderia cepacia</i>	>250
	<i>Stenotrophomonas maltophilia</i>	4,3
	<i>Proteus mirabilis</i>	>250
	<i>Proteus vulgaris</i>	>79,1
	<i>Candida albicans</i>	>250
HBD3 (-)	<i>Peptostreptococcus micros</i>	>250
	<i>Actinomyces naeslundii</i>	7,2
	<i>Actinomyces israelii</i>	9,0
	<i>Streptococcus sanguis</i>	7,6
	<i>Streptococcus mutans</i>	5,0
	<i>Actinobacillus actinomycetemcomitans</i>	>250
	<i>Fusobacterium nucleatum</i>	4,5
	<i>Porphyromonas gingivalis</i>	5,7
	<i>Escherichia coli</i>	5,1
	<i>Candida tropicalis</i>	3,5
	<i>Candida parapsilosis</i>	12,4
	<i>Candida krusei</i>	2,0
	<i>Candida glabrata</i>	33,8
	<i>Candida albicans</i>	7,1

Staphylococcus aureus, VREF – *Enterococcus faecalis*.

HNP [17].

[18].


in vivo

HNP

[19].
HNP
in vitro

HNP,
IL-8

[20].



[24].
(10-100),
5-10%
[25], -
Toll- (« »)
(TLR – Toll-like
receptors). TLR
[14,15,16].

HBD2)

HBD

[21, 22, 23].

[27]. HNP1
 -1 -2;
 (VSV
 - vesicular stomatitis virus)
 HNP1
 2

HNP1-3	-1, -1, -2,	
HNP1		
HNP4	-1	
HD5		
HBD1	-1,	
HBD2	-1, ;	
HBD3	-1,	
HBD6	(in vivo)	

[27]. , HBD2 -
 [33]. -
 () - , -
 1993 [28]. -
 , -
 in vitro. , -
 , / -
 gp120 CD4, - , HNP1-3 [34].
 [29,30,31]. , -
 , - 1 (
 [21, 23]. DEFB1)
 HNP - , -
 HNP [32]. - 82% -
 HNP , 90% -
 , - DEFB1 [35]. -

a5h1

[41].

DEFB1

[35,36].
DEFB1

()

- HBD2 (DEFB4)

[37]. - HNP2

HBD2 HNP2 [38].
in vitro

CCR6⁺ CCR6⁻
(mDC), HNP2

CCR6⁻
in vivo.

[39].

DEFB4,

NIGsFv
IGsFv.
CCR6

HNP

HNP

[42].
()

HNP

[43].

HNP

HBD

HBD2 HBD4
in vitro

Pseudomonas aeruginosa
50 [8].

HBD,

TCR-

HBD ()

MHCII.

»

[40].

HNP1 HNP3,

HBD

HBD (

)

, HBD

»

[4].

CD4,
[44].

[45,46].

1. Reddy K.V. Antimicrobial peptides: premises and promises / K.V. Reddy, R.D. Yedery, C. Aranha // *Int. J. Antimicrob. Agents.* – 2004. – Vol. 24, N 5. – P. 536–547.

2. Bals R. Epithelial antimicrobial peptides in host defense against infection / R. Bals // *Resp. Res.* – 2000. – N 1. – P. 141–150.

3. Selsted M. E. Purification and antibacterial activity

of antimicrobial peptides of rabbit granulocytes / M. E. Selsted, D. Szklarek, R. I. Lehrer // *Infect. Immun.* – 1984. – Vol. 45, N 1. – P. 150–154.

4. Budikhina A.S. Defensins – multifunctional cations peptides of human / Budikhina A.S., Pinegin B.V. // *Immunopathology, allergology, infectology.* 2008. – Vol. 2, N 1. – P. 31–40.

5. Selsted M. E. Activity of rabbit leukocyte peptides against *Candida albicans* / M. E. Selsted, D. Szklarek, T. Ganz // *Infect. Immun.* – 1985. – Vol. 49, N 2. – P. 202–206.

6. Lehrer R. I. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations / R. I. Lehrer, T. Ganz, D. Szklarek // *J. Clin. Invest.* – 1988. – Vol. 81, N 18. – P. 1829–1835.

7. Ericksen B. Antibacterial activity and specificity of the six human α -defensins / B. Ericksen, Z. Wu, W. Lu // *Infect. Immun.* – 2005. – Vol. 49, N 1. – P. 269–275.

8. Joly S. Human α -Defensin 2 and 3 demonstrate strain-selective activity against oral microorganisms / S. Joly, C. Maze, P. B. McCray // *J. Clin. Microbiol.* – 2004. – Vol. 42, N 3. – P. 1024–1029.

9. Significance of human α -defensins in the epithelial lining fluid of patients with chronic lower respiratory tract infections / S. Yanagi, J. Ashitani, K. Imai [et al.] // *Clin. Microbiol. Infect.* – 2007. – Vol. 13, N 1. – P. 63–69.

10. Kris De Smet. Human antimicrobial peptides: defensins, cathelicidins and histatins / De S. Kris, C. Roland // *Biotechnology Letters.* – 2005. – Vol. 27, N 13. – P. 1337–1347.

11. Yount N. Y. Immunoconsilium: Perspectives in Antimicrobial Peptide Mechanisms of Action and Resistance / N. Y. Yount, M. R. Yeaman // *Protein and Peptide Letters.* – 2005. – P. 49–67.

12. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes / B. L. Kagan, M. E. Selsted, T. Ganz, R. I. Lehrer // *Proc. Natl. Acad. Sci. USA.* – 1990. – Vol. 87, N 2. – P. 210–214.

13. Fujii G. Defensins promote fusion and lysis of negatively charged membranes / G. Fujii, M. E. Selsted, D. Eisenberg // *Protein Sci.* – 1993. – Vol. 2, N 13. – P. 1301–1312.

14. Differential scanning microcalorimetry indicates that human defensin, HNP-2, interacts specifically with biomembrane mimetic systems / K. Lohner, A. Latal, R. I. Lehrer, T. Ganz // *Biochemistry.* – 1997. – Vol. 36, N 15. – P. 1525–1531.

15. Huang H. W. Action of antimicrobial peptides: two-state model / H. W. Huang // *Biochemistry.* – 2000. – Vol. 39, N 8. – P. 8347–8352.

16. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α -helical antimicrobial and cell non-selective membrane-lytic peptides / Y. Shai // *Biochim. Biophys. Acta.* – 1999. – N 1462. – P. 55–70.

17. Human neutrophil defensin and serpins form complexes and inactivate each other / A. V. Panyutich, P. S. Hiemstra, S. van Wetering, T. Ganz // *Am. J. Respir. Cell Mol. Biol.* – 1995. – Vol. 12, N 3. – P. 351–357.

18. Zhang H. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion / H. Zhang // *Am. J. Physiol. Lung Cell. Mol. Physiol.* – 2001. – Vol. 280, N 9. – P. L947–L954.
19. Mammalian defensins in immunity: more than just microbicidal / D. Yang, A. Biragyn, L. W. Kwak, J. J. Oppenheim // *Trends Immunol.* – 2002. – Vol. 23, N 2. – P. 291–296.
20. ADP- ribosyltransferase-specific Modification of Human Neutrophil Peptide-1 / G. Paone, L. A. Stevens, R. L. Levine [et al.] // *J. Biol. Chem.* – 2006. – Vol. 281, N 25. – P. 17054–17060.
21. Monocyte-chemotactic activity of defensins from human neutrophils / M. C. Territo, T. Ganz, M. E. Selsted, R. Lehrer // *J. Clin. Invest.* – 1989. – Vol. 84, N 20. – P. 2017–2020.
22. Chertov O. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils / O. Chertov // *J. Biol. Chem.* – 1996. – Vol. 271, N 28. – P. 2935–2940.
23. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells / D. Yang, Q. Chen, O. Chertov, J. J. Oppenheim // *J. Leukoc. Biol.* – 2000. – Vol. 68, N 1. – P. 9–14.
24. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense / D. Yang, A. Biragyn, D. M. Hoover [et al.] // *Ann. Rev. Immunol.* – 2004. – Vol. 22, N 1. – P. 181–215.
25. Biragyn A. Toll-like receptor 4-dependent activation of dendritic cells by α -defensin 2 / A. Biragyn // *Science.* – 2002. – Vol. 298, N 10. – P. 1025–1029.
26. Klotman M. E. Defensins in innate antiviral immunity / M. E. Klotman, T. L. Chang // *Nat. Rev. Immunol.* – 2006. – Vol. 6, N 6. – P. 447–456.
27. Daher K. A. Direct inactivation of viruses by human granulocyte defensins / K. A. Daher, M. E. Selsted, R. I. Lehrer // *J. Virol.* – 1986. – Vol. 60, N 10. – P. 1068–1074.
28. Defensins inhibit HIV replication in vitro / H. Nakashima, N. Yamamoto, M. Masuda, N. Fujii // *AIDS.* – 1993. – Vol. 7, N 11. – P. 1129.
29. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4 / L. Furci, F. Sironi, M. Tolazzi [et al.] // *Blood.* – 2007. – Vol. 109, N 29. – P. 2928–2935.
30. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity / T. L. Chang, J. J. Vargas, A. DelPortillo, M. E. Klotman // *J. Clin. Invest.* – 2005. – Vol. 115, N 7. – P. 765–773.
31. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication / M. E. Quinones-Mateu, M. M. Lederman, Z. Feng [et al.] // *AIDS.* – 2003. – Vol. 17, N 1. – P. F39–48.
32. Contribution of human α -defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor / L. Zhang, W. Yu W., T. He [et al.] // *Science.* – 2002. – Vol. 298, N 9. – P. 995–1000.
33. Duits L. A. Rhinovirus increases human α -defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells / L. A. Duits // *FEMS Immunol. Med. Microbiol.* – 2003. – Vol. 38, N 1. – P. 59–64.
34. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes / A. Lichtenstein, T. Ganz, M. E. Selsted, R. I. Lehrer // *Blood.* – 1986. – Vol. 68, N 14. – P. 1407–1410.
35. Human α -defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma / C. Q. Sun, R. Arnold, C. Fernandez-Golarz [et al.] // *Cancer Res.* – 2006. – Vol. 66, N 8. – P. 8542–8549.
36. Functional analysis of the host defense peptide Human Defensin-1: new insight into its potential role in cancer / R. S. Bullard, W. Gibson, S. K. Bose [et al.] // *Mol. Immunol.* – 2008. – Vol. 45, N 8. – P. 839–848.
37. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo / P. Hubert, L. Herman, C. Maillard [et al.] // *FASEB J.* – 2007. – Vol. 21, N 27. – P. 2765–2775.
38. Human alpha-defensins block papillomavirus infection / C. B. Buck, P. M. Day, C. D. Thompson [et al.] // *Proc. Natl. Acad. Sci. USA.* – 2006. – Vol. 103, N 5. – P. 1516–1521.
39. Dendritic cells induce the death of human papillomavirus-transformed keratinocytes / P. Hubert, S. L. Giannini, A. Vanderplasschen [et al.] // *FASEB J.* – 2001. – Vol. 15, N 25. – P. 2521–2523.
40. Biragyn A. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens / A. Biragyn // *J. Immunol.* – 2001. – Vol. 167, N 65. – P. 6644–6653.
41. Inhibition of pathologic retinal neovascularization by α -defensins / M. Economopoulou, K. Bdeir, D. B. Cines [et al.] // *Blood.* – 2005. – Vol. 106, N 37. – P. 3831–3838.
42. Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines / M. Nishimura, Y. Abiko, Y. Kurashige [et al.] // *J. Dermatol. Sci.* – 2004. – Vol. 36, N 1. – P. 87–95.
43. Kalita A. Role of Human Neutrophil Peptide-1 as a Possible Adjunct to Antituberculosis Chemotherapy / A. Kalita, I. Verma, G. K. Khuller // *J. Infectious Diseases.* – 2004. – Vol. 190, N 14. – P. 1476–1480.
44. . . . / . . . , – 2011. – 5 (43). – . 18–26.
45. . . . / . . . , . . . [.] // . . . – 2005. – 7. – . 65–69.
46. . . . / . . . – 2012. – 1 (67). – . 79–82.